ForSight VISION5, Inc., was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5's lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive medication.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/16/14 | $15,000,000 | Series C |
Delphi Ventures H.I.G. BioVentures Morgenthaler Technology Partners Versant Ventures | undisclosed |
